This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Breast cancer; prostate cancer

Androgen receptor; cyclin D1 (CCND1; BCL1)

In vitro and mouse studies identified acetamide analog small molecules that could help treat prostate and other cancers. In human prostate cancer cell lines, two acetamide analogs induced apoptosis and decreased both CCND1 and androgen receptor expression compared with vehicle. In mouse xenograft models of prostate cancer or breast cancer, the lead analog decreased tumor growth compared with vehicle without causing significant toxicity. Ongoing work includes testing the lead compound in human melanoma cell lines and mouse models of melanoma and other cancers.

SciBX 6(33); doi:10.1038/scibx.2013.887
Published online Aug. 29, 2013

Unpatented; licensing status not applicable

Rico-Bautista, E. et al. Oncotarget 4, 1212-1229 (2013)
Contact: Dieter A. Wolf, Sanford-Burnham Medical Research Institute, La Jolla, Calif.
e-mail:

dwolf@sanfordburnham.org
Contact: Elizabeth Rico-Bautista, same affiliation as above
e-mail:

erico@sanfordburnham.org